Erik Greb January 10, 2022 The US Food and Drug Administration (FDA) has approved the dual orexin receptor antagonist daridorexant (Quviviq) for the treatment of insomnia in adults, the drug’s manufacturer, Idorsia, has announced. The FDA’s decision was based partly on a phase 3 trial of adults with moderate-to-severe insomnia who were randomly assigned to receive 25...